This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
ALKSPositive Net Change VRTXPositive Net Change CRMDPositive Net Change CRSPPositive Net Change
biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
by Sundeep Ganoria
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
ASNDPositive Net Change AUTLPositive Net Change IMRXNegative Net Change ANROPositive Net Change
biotechs earnings medical
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
by Ahan Chakraborty
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
by Zacks Equity Research
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
ALKSPositive Net Change ANIPPositive Net Change CRMDPositive Net Change IOVAPositive Net Change
biotechs earnings medical
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
BIIBPositive Net Change ALKSPositive Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
by Zacks Equity Research
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
SNYPositive Net Change NVAXNegative Net Change ANIPPositive Net Change ARQTPositive Net Change
biotechs earnings
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
ALKSPositive Net Change ANIPPositive Net Change CRMDPositive Net Change ALLONo Net Change
biotechs earnings medical
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
by Zacks Equity Research
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
PBYIPositive Net Change ANIPPositive Net Change SNDXPositive Net Change ARQTPositive Net Change
biotechs earnings
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
LLYPositive Net Change NKTRPositive Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
by Zacks Equity Research
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
REGNPositive Net Change ANIPPositive Net Change ACADPositive Net Change NTLAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
ALKSPositive Net Change ANIPPositive Net Change CRMDPositive Net Change RVMDPositive Net Change
biotechs earnings medical
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
by Zacks Equity Research
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment
GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
ANIPPositive Net Change ACADPositive Net Change SNDXPositive Net Change ARQTPositive Net Change
biotechs earnings
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
by Zacks Equity Research
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
ALKSPositive Net Change JAZZPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs earnings medical
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
FOLDPositive Net Change CPRXPositive Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
by Zacks Equity Research
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
ALKSPositive Net Change FOLDPositive Net Change CRMDPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
FOLDPositive Net Change ANIPPositive Net Change ACADPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
by Zacks Equity Research
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ALKSPositive Net Change FOLDPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
AZNPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs pharmaceuticals
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
by Zacks Equity Research
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
VRTXPositive Net Change ANIPPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
by Zacks Equity Research
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
ANIPPositive Net Change NTLAPositive Net Change MIRMPositive Net Change ARQTPositive Net Change
biotechs earnings
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
by Zacks Equity Research
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
RHHBYPositive Net Change ALKSPositive Net Change EXELPositive Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
by Zacks Equity Research
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
REGNPositive Net Change BEAMPositive Net Change FOLDPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals